Infree

Research use only, not for human use.

Infree is a prodrug of indomethacin. It acts as a nonsteroidal anti-inflammatory drug (NSAID) and disease-modifying anti-rheumatic drug (DMARD).

Infree is a prodrug of indomethacin. It acts as a nonsteroidal anti-inflammatory drug (NSAID) and disease-modifying anti-rheumatic drug (DMARD).

Indometacin farnesil (IMF) is a newly synthesized prodrug of indomethacin designed to reduce the occurrence of side-effects by esterification of the carboxyl group of indomethacin with farnesol. This modification is intended to decrease the extraction and subsequent rapid metabolism of the drug by the liver, so that lymphatic absorption would become a major route, and it was also anticipates that hydrolytic enzymes present in plasma and tissues, including inflamed tissue, would release indomethacin effectively from IMF.

Indomethacin farnesil (IMF) can effectively release indomethacin when administered locally. Animal Model:Rats.Dosage:50 nmol a rat paw.Administration:Once.Result:Reduced the level of PGE2 in a dose dependent manner.

——

Others

Other Targets

others

——

——

85801-02-1

562.14

C34H40ClNO4

>98% (HPLC)

——

Clc1ccc(cc1)C(=O)n3c2ccc(cc2c(CC(=O)OC\C=C(/C)CC\C=C(/C)CC\C=C(/C)C)c3C)OC

3711-Trimethyldodeca-2610-trien-1-yl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate

(-20℃)

With Ice Pack

≥ 2 years